Cargando…

Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia

Detalles Bibliográficos
Autores principales:	Sakr, Yasser, Bensasi, Hatim, Taha, Ahmed, Bauer, Michael, Ismail, Khaled
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041240/ https://www.ncbi.nlm.nih.gov/pubmed/33846824 http://dx.doi.org/10.1007/s00134-021-06395-1

Ejemplares similares

Characteristics and outcome of critically ill patients with coronavirus disease-2019 (COVID-19) pneumonia admitted to a tertiary care center in the United Arab Emirates during the first wave of the SARS-CoV-2 pandemic. A retrospective analysis
por: Ismail, Khaled, et al.
Publicado: (2021)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation
por: Hofmann-Winkler, Heike, et al.
Publicado: (2020)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
por: Kosinsky, Yuri, et al.
Publicado: (2022)

Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
por: Kim, Gwanyoung, et al.
Publicado: (2023)

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
por: Tobback, Els, et al.
Publicado: (2022)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
por: Bittmann, Stefan, et al.
Publicado: (2020)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
por: Karolyi, M., et al.
Publicado: (2022)

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
por: Kitagawa, Junsaku, et al.
Publicado: (2021)

A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
por: Chupp, Geoffrey, et al.
Publicado: (2022)

Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial
por: Keitel, Verena, et al.
Publicado: (2021)

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
por: Ota, Shinichiro, et al.
Publicado: (2016)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2020)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2021)

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19
por: Kim, Yeon-Sook, et al.
Publicado: (2022)

Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
por: Okajima, Masaki, et al.
Publicado: (2020)

Outcomes of Covid-19 organizing pneumonia in critically ill patients
por: Rocha, Ana Silva, et al.
Publicado: (2021)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

Long term outcomes of critically ill COVID-19 pneumonia patients: early learning
por: McCue, Claire, et al.
Publicado: (2020)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial
por: Terada, Jiro, et al.
Publicado: (2022)

Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
por: Assylbekova, Akmaral, et al.
Publicado: (2022)

Adjuvant corticosteroid therapy for critically ill patients with COVID-19
por: Lu, Xiaofan, et al.
Publicado: (2020)

Advances in antibiotic therapy in the critically ill
por: Jia, Rufu, et al.
Publicado: (2016)

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2
por: Zhu, Haixia, et al.
Publicado: (2020)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

Clinical phenotypes of critically ill COVID-19 patients
por: Azoulay, Elie, et al.
Publicado: (2020)

Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19
por: Sharma, Tanuj, et al.
Publicado: (2022)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Different barriers to nutritional therapy among critically-ill patients with COVID-19
por: Aguila, Enrik John T., et al.
Publicado: (2021)

Ventilator-associated pneumonia in critically-ill patients with COVID-19 in a setting of selective decontamination of the digestive tract
por: van der Meer, Sinta B., et al.
Publicado: (2021)

Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia
por: Zhu, Yingjie, et al.
Publicado: (2023)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Thromboelastography Might Be More Applicable to Guide Anticoagulant Therapy than Fibrinolytic Therapy in Critically Ill Patients with COVID-19
por: Brubaker, Lisa, et al.
Publicado: (2021)

Thromboelastography MightBe More Applicable to Guide Anticoagulant Therapy than Fibrinolytic Therapy in Critically Ill Patients with COVID-19
por: Brubaker, Lisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l916tvc5vu8ghr50kdmbss9bn7